The Hematologist

July August 2012 Vol 9 Issue 4

July-August 2012, Volume 9, Issue 4

Diffusion

back to top

Ask the Hematologist

back to top

Mini Review

  • Oncometabolites Mediate Alterations in Covalent Cytosine Modifications in AMLJuly 01, 2012

    Cytogenetically normal acute myeloid leukemia (CyN-AML) makes up 40 to 50 percent of cases of adult AML. The heterogeneous nature of CyN-AML makes prognosis uncertain, and despite the clinical heterogeneity, induction therapy remains largely uniform. Technological advances in DNA sequencing, however, are providing new insights into the molecular basis of CyN-AML, suggesting new diagnostic and prognostic categories and novel approaches to therapy.

back to top

Clinical Trials Corner

back to top

President's Column

back to top

Op-Ed

back to top